Project Grant R21CA302685
Award Date 5/14/26
Completion Date 4/30/28
Dollars Obligated $415K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- Federal Grant Award Summary Mayo Clinic received a $484,803 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 18, 2025, with completion scheduled for July 31, 2030. This research initiative focuses on elucidating glioma risk and improving patient outcomes by integrating germline and somatic genetics analysis. The project addresses critical gaps in understanding the functional relevance of 30 known germline...
- Federal Grant Award Summary Mayo Clinic received a $667,710 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on March 20, 2026, with a completion date of February 28, 2031. The grant supports a randomized Phase 2 clinical trial investigating blood-based biomarkers to optimize treatment strategies for patients with oligometastatic castration-sensitive prostate cancer (OMCSPC). The research evaluates prostate cancer-derived...
- Federal Grant Award Summary Mayo Clinic received a $2.46 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2029. The grant funds research and development of NKG7-armed tumor-infiltrating lymphocyte (TIL) therapy for metastatic uveal melanoma treatment. This immunotherapy research initiative represents the DHA's investment in advanced biomedical research...
- Federal Grant Award Summary Mayo Clinic received a $367,731 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 12, 2026, with a completion date of April 30, 2031. The grant supports research investigating ADAR1 (Adenosine Deaminase Acting on RNA 1) protein's role in DNA replication and its potential as a therapeutic target for breast cancer treatment. The research focuses on the nuclear ADAR1P110 isoform's...
- Federal Project Grant Award Summary Mayo Clinic received a $307,381 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded July 1, 2026, with a completion date of June 30, 2031. This five-year research initiative focuses on exploiting SPOP (Speckle Type BTB/POZ Protein) mutations to develop novel synthetic lethality mechanisms for treating prostate cancer, particularly castration-resistant prostate cancer (CRPC). The research...
- Federal Project Grant Award Summary Mayo Clinic received a $161,400 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period August 1, 2025 through July 31, 2027. The award supports research to develop and validate innovative ferroptosis-based therapeutic approaches targeting cholangiocarcinoma (CCA), a highly lethal malignancy of the liver and biliary tract with a five-year survival rate below 10%. The...
- Federal Project Grant Award Summary Mayo Clinic received a $676,067 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 13, 2026, with a completion date of February 28, 2031. The award funds research to address thyroid cancer overdiagnosis by developing and validating artificial intelligence (AI) and natural language processing (NLP) systems to identify and characterize incidental thyroid nodules (ITNs)...
- GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $607,249 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective May 1, 2026 through April 30, 2031. The grant supports research to define the role of MAFG (a transcription factor) in melanocyte transformation and melanoma development. The research will utilize an embryonic stem cell-genetically engineered mouse...